According to a newly published market research report by 24LifeSciences, global Graft Versus Host Disease (GVHD) Treatment market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period 20252031.
Graft versus Host Disease, a serious complication following stem cell or bone...
Primary HLH is a life-threatening genetic condition that often requires definitive treatment beyond symptom control. The advancement of hematopoietic stem cell transplantation (HSCT) has played a central role in shaping the Primary Haemophagocytic Lymphohistiocytosis Market. For many patients, transplantation remains the only curative therapy capable of correcting the underlying immune defect....
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt